An Overview on Intranasal Drug Delivery System: Recent Technique and Its Contribution in Therapeutic Management

  • Anu Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology (MIET), NH-58, Delhi-Roorkee Highway, Meerut-250005, Uttar Pradesh, India
  • S K Gupta Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology (MIET), NH-58, Delhi-Roorkee Highway, Meerut-250005, Uttar Pradesh, India
  • Shobhit Kumar Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology (MIET), NH-58, Delhi-Roorkee Highway, Meerut-250005, Uttar Pradesh, India

Abstract

Nasal drug administration has been used as an important another route for the systemic availability of drugs. Intranasal route has large surface area, high total blood flow, avoidance of first-pass metabolism, porous endothelial membrane, and ready accessibility. For nasal route administration various drugs including peptide and protein drugs, for systemic medication has been widely used in recent few years. This review article highlights the importance, strategies and advantages of the nasal drug delivery systems. Various methods are discussed here for increasing the residence time of drug formulations in the nasal cavity, for improving nasal drug absorption. In this review article we discuss the effects of bioadhesive drug delivery systems on nasal drug administration. Drug delivery systems (such as nanoemulsion, microspheres, liposome and gels) have good bioadhesive characteristics which swell easily when in contact with the nasal mucosa. These types of drug delivery systems protect the drug from enzymatic degradation in nasal secretions and also control the rate of drug clearance from the nasal cavity.


 

Keywords: Protein, Peptides, Intranasal drug delivery, Permeation enhancer, Bioavailability

References

1. Kumar S, Ali J, Baboota S. Design Expert® supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease. Nanotechnology. 2016; 27: 435101.
2. Kumar S, Dang S, Nigam K, Ali J, Baboota S. Selegiline nano formulation in attenuation of oxidative stress and up regulation of dopamine in the brain for the treatment of Parkinson's disease. Rejuvenation Res. 2018; 21: 464-476.
3. Hicke A. J. Pharmaceutical Inhalation Aerosol Technology, 2nd ed Marcel Dekker, Inc: NewYork, 2004
4. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release. 2003; 87: 187–198.
5. Ugwoke MI, Verbek N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesion drug delivery. J Pharm Pharmacol. 2001; 59: 3–22.
6. Sharma PK, Garg G, Salim M. Review on nasal drug delivery system with recent advancement. Int. J. Pharm. Pharm. Sci. 2011; 3(2): 6-11.
7. Stenehjem DD, Hartz AM, Bauer B, Anderson GW. Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier. Future Med. Chem. 2009; 9:1623-1641.
8. Arora P, Sharma GS. Permeability issues in nasal drug delivery. Drug Discov Today. 2002; 7: 967–975.
9. Marttin E, Nicolaas GM, Schipper J, Coos V, Frans WH. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Del Rev. 1997; 29:13-38.
10. Choi HG, Jung JH, Ryu JM. Int J of pharm. 1998; 165: 33-44.
11. Singh kumar Arun. Nasal cavity: A promising transmucosal platform for drug delivery and research approach from nasal to brain targeting. Journal of Drug Delivery and Therapeutics. 2012; 23:22-33.
12. Chajed S, Sangle S, Barhate S. Advantagious nasal drug delivery system; A review. International journal of pharmaceutical science and research. 2011; 2(6):1322-1336.
13. Machida M. Effects of surfactants and protease inhibitors on nasal absorption of recombinant human granulocyte colony stimulating factor (rHG-CSF) in rats. Biol. Pharm. Bull. 1994; 17:1375–1378
14. Watanabe H, Tsuru H. Nippon Yakurigaku Zasshi. 1999; 113: 211–218.
15. Gupta B. K, Kumar S, Kaur H, Ali J, Baboota S. Attenuation of oxidative damage by Coenzyme Q10 loaded nanoemulsion via oral route for the management of Parkinson's disease. Renjuvention Res. 2018; 21: 232-248.
16. CornazA L, Buri P. Nasal mucosa as an absorption barrier. Eur. J. Pharm. Biopharm. 1994; 40: 261–270.
17. Gannu Praveen Kumar and Kiran S. Strategies and prospects of nasal drug delivery systems. Indian Journal of Pharmaceutical Science and Research. 2012; 2(1):33-41.
18. Ohwaki K, Ando H, Watanabe S, Miyake Y. Effects of Krenistsky, Amino acid ester prodrugs of acyclovir, Antiviral dose, pH, and osmolarity on nasal absorption of secretin in Chem Chemother. 1992; 3:157–164.
19. Krishnamoorthy R, Mitra NK. Prodrugs for nasal delivery. Adv Drug Deliv Rev.1998; 29: 135–146.
20. Duquesnoy C, Mamet JP, Sumner D and Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcut anus, oral, rect al and intranasal administration. Eur J Pharm Sci. 1998; 6:99-104.
21. Zaheer A, Swamy S. Mucoadhesive Polymers: Drug Carriers for Improved Nasal Drug Delivery. Indian Journal of Novel Drug Delivery. 2012; 4(1): 2-16.
22. Behl CR, Pimplaskar NK, Sileno AP, Demeireles J, Romeo VD. Effect of physicochemical properties and other factors on nasal drug delivery. Advanced drug delivery Reviews. 1998; 89-116.
23. Sakane T. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem. Pharm. Bull. (Tokyo). 1991; 39: 2456–2458.
24. Ibrahim A, Alsarra AY, Hamed Fars KA, Gamal M, Maghraby E. Vesicular Systems for Intranasal Drug Delivery, K. K. Jain (ed.), Drug Delivery to the Central Nervous System, Neuromethods 45, DOI 10.1007/978-1-60761-529-3_8
25. Chein YW, Su KES, Chang SF. Nasal systemic drug deliver Dekker. 1989.
26. Parvathi M. Intranasal drug delivery to brain: an overview. International journal of research in pharmacy and chemistry. 2012; 2(3): 889-895.
27. Mahour R, Sahni JK, Sharma S, Kumar S, Ali J, Baboota S. Nanoemulsion as a tool for improvement of cilostazol oral bioavailability. J. Mol. Liq. 2015; 212: 792-798.
28. Pandey YR, Kumar S, Gupta BK, Ali J, Baboota S. Intranasal delivery of paroxetine nanoemulsion via the olfactory region for the management of depression: formulation, behavioural and biochemical estimation. Nanotechnolog. 2016; 27: 025102.
29. Sindhu P, Kumar, S, Iqba, B, Ali J, Baboota S. Duloxetine loaded-microemulsion system to I prove behavioral activities by upregulating serotonin and norepinephrine in brain for the treatment of depression. J. Psychiatr. Res. 2018; 99: 83-95.
Statistics
104 Views | 125 Downloads
How to Cite
Anu, S K Gupta, and Shobhit Kumar. “An Overview on Intranasal Drug Delivery System: Recent Technique and Its Contribution in Therapeutic Management”. Current Research in Pharmaceutical Sciences, Vol. 9, no. 2, Aug. 2019, doi:10.24092/CRPS.2019.090201.
Section
Review Articles